What is the current Transfusion Diagnostic Equipment market size?

Global Transfusion Diagnostic Equipment market size reached USD 4.7 billion in 2023, driven by rising blood-bank automation and stringent cross-match regulations.

What is the forecast growth rate for the next five years?

Analysts project a 6.2% CAGR through 2028, propelled by emerging-market hospital upgrades and expanded molecular serology menus.

What are the key market drivers?

Growth stems from chronic-disease prevalence, trauma caseloads, voluntary-donor screening mandates, and shift toward high-throughput, walk-away analyzers.

Which challenges could restrain expansion?

High instrument sticker prices, reimbursement pressure, skilled-tech shortages, and fragmented supply chains for rare antisera can dampen uptake.

Which regions lead adoption today?

North America holds 38% share; Europe follows with 29%. Asia-Pacific is fastest-growing, fueled by China and India's blood-safety modernization.

Who are the top companies in the space?

Bio-Rad, Immucor, Ortho Clinical Diagnostics, Grifols, Quotient, and Danaher dominate through broad reagent portfolios and integrated analyzer platforms.

Where are the biggest future opportunities?

Point-of-care pre-transfusion testing, AI-supported antibody identification, and disposable lab-on-chip cassettes for remote clinics present high-growth niches.

How is technology reshaping the market?

Next-generation NAT, microarray phenotyping, and cloud-based traceability shorten turnaround times, reduce human error, and boost blood-stock efficiency.

What does the regulatory landscape look like?

Stringent FDA, CE, and WHO approvals require clinical-grade validation; upcoming IVDR in Europe tightens post-market surveillance, raising compliance costs.

What Is the Global Transfusion Diagnostic Equipment Market Worth in 2026?

Transfusion Diagnostic Equipment by Application (Pre-Transfusion Diagnostic, Post Transfusion Diagnostic), by Types (Molecular HLA Typing Diagnose Equipment, HLA Serology Diagnose Equipment, HLA Antibody Diagnostics Equipment), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $4800 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $4800 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transfusion Diagnostic Equipment Market Overview

Transfusion diagnostic equipment comprises the analytical platforms, reagents, and software used to ensure the safety and compatibility of blood products prior to transfusion. With the Transfusion Diagnostic Equipment market size valued at approximately USD 4.9 billion in 2025, the sector is poised for steady industry expansion as hospitals and blood banks modernize testing capacity amid rising surgical volumes and complex oncology therapies. The market forecast through 2033 points to a 5–6 % CAGR, underpinned by a global push toward molecular genotyping, automation, and data-driven traceability that mitigates transfusion-transmitted infections and alloimmunization risk.

Loading chart…

North America remains the largest revenue contributor, propelled by premium pricing for fully automated systems and stringent FDA quality standards, while Asia-Pacific is the fastest-growing region thanks to expanding healthcare budgets, localized manufacturing, and government-led blood-safety initiatives. Key forces reshaping competitive dynamics include the shift to molecular immunohematology that shortens turnaround times, tightening regulatory scrutiny on supply-chain integrity, and intensifying price pressure as group-purchasing organizations consolidate procurement across health networks.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 billion
Revenue forecast in 2033	7.77 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Immucor; Johnson & Johnson; Quotient; Beckman Coulter; Becton Dickinson; Biokit; BioMerieux; Siemens; Roche; Fujirebio; Diagast
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated shift toward molecular immunohematology and full-automation analyzers is propelling replacement demand; hospitals aiming to reduce TAT for type-and-screen are upgrading to next-gen Transfusion Diagnostic Equipment, adding 8–10% incremental volume to the installed base annually.

Rising alloimmunization in chronically transfused oncology and sickle-cell populations is widening reimbursement for extended antigen-typing, directly lifting average revenue per test and pulling through high-margin reagent contracts that underpin the Transfusion Diagnostic Equipment market size expansion.

Restraints

Capital budgets remain skewed toward therapeutic platforms; with a single fully automated analyzer priced at USD 0.9–1.4M, CFOs are deferring purchase orders even as patient volumes rebound, elongating replacement cycles to 7–9 years and compressing near-term growth forecast visibility.

Ongoing supply-chain tightness for monoclonal reagents and rare antisera has elevated COGS by 12–15% since 2022; vendors absorbing input inflation cannot fully pass through pricing in tender-driven public markets, eroding gross margin and discouraging aggressive capacity additions.

Opportunities

Emerging-market blood operators are piloting reagent-rental and annuity-style pay-per-test models, lowering upfront costs and opening a 1,200–1,500 site opportunity across LATAM and ASEAN where manual testing still dominates; early movers can lock in multi-year reagent streams before local competition scales.

Integration of machine-learning algorithms for antibody identification into CE-marked devices creates a differentiated software-as-product (SaaP) upsell—labs can subscribe to algorithm updates, adding 5–7% recurring ARPU without incremental hardware, a lever to outpace historical growth forecast trajectories.

Challenges

Regulatory harmonization lag—especially between FDA’s recent 510(k) cybersecurity mandates and EU IVDR’s post-market surveillance rules—forces manufacturers to run dual validation tracks, stretching R&D resources and complicating global launch sequencing.

Heightened competition from non-traditional point-of-care molecular players entering bedside pre-transfusion testing threatens to commoditize high-throughput immunoassay segments; price compression in private-lab tenders is already tracking 4–6% Y/Y, challenging vendors to defend share without sacrificing margin in the Transfusion Diagnostic Equipment market.

Market Segmentation

Loading chart…

Application-based Transfusion Diagnostic Equipment segmentation separates demand into Blood Grouping, Disease Screening, and Cross-matching. Blood Grouping accounts for the largest share because every unit transfused first requires ABO/Rh determination; its high-frequency, repeat-test nature underpins a steady replacement cycle of analyzers and reagents. Disease Screening, while lower in test volume per patient, commands premium pricing owing to multiplex NAT platforms that simultaneously detect HIV, HBV, HCV, and emerging pathogens; growth is tied to nucleic-acid amplification penetration rates in emerging markets. Cross-matching generates fewer daily runs yet demands sophisticated gel-cards or automated solid-phase systems to ensure serologic compatibility; as hospitals centralize transfusion services, average instrument throughput rises, lifting capital expenditure per site. Collectively, these application segments shape procurement budgets, with Blood Grouping anchoring volume and Disease Screening amplifying value.

Types classify instruments into Automated Analyzers, Semi-automated Analyzers, and Manual Test Kits, each mapping to distinct laboratory economics. Automated Analyzers dominate revenue because high-throughput facilities consolidate testing to reduce tech-time per sample; walk-away systems integrate sample tracking, driving 5-7 year replacement cycles supported by multi-year reagent contracts. Semi-automated Analyzers occupy mid-sized hospitals balancing budget constraints with moderate volumes; these open-platform units allow reagent choice, sustaining price competition among suppliers. Manual Test Kits persist in rural blood banks and field emergencies where capital budgets are minimal; despite low unit prices, the segment remains sizeable due to sheer facility count. The Transfusion Diagnostic Equipment market taxonomy thus reveals a technology staircase—from manual to fully automated—aligned with regional healthcare funding rather than clinical need alone.

Transfusion Diagnostic Equipment Segmentation Breakdown7 items

Application

Pre-Transfusion Diagnostic

Post Transfusion Diagnostic

Types

Molecular HLA Typing Diagnose Equipment

HLA Serology Diagnose Equipment

HLA Antibody Diagnostics Equipment

Regional Insights

Loading chart…

North America dominates the Transfusion Diagnostic Equipment market with a 38% share, driven by a mature ecosystem, stringent FDA hemovigilance mandates, and rapid uptake of molecular immunohematology platforms. Venture funding exceeding USD 180 million in 2023 continues to underwrite automation upgrades, reinforcing the regional forecast for low-single-digit growth despite pricing pressure.

Europe (27%) benefits from converging EU Blood Directives, centralized tendering, and a shift toward pathogen-reduced components; Germany and France are investing in next-generation analyzers, while CE-marked NAT systems accelerate Transfusion Diagnostic Equipment market growth.

Asia Pacific is the fastest-growing region (value-based CAGR >9%), spurred by expanding donor pools in China and India, government subsidies for blood safety, and greenfield PPP projects for plasma fractionation. Japan’s aging demographic fuels demand for extended phenotyping, underpinning the bullish regional forecast.

Latin America (10%) is scaling serology standardization programs, supported by PAHO procurement funds; Brazil’s mandatory HIV/HBV/HCV NAT rollout and Mexico’s hospital PPPs drive double-digit adoption, though forex volatility tempers capital budgets.

Middle East & Africa (7%) sees pockets of momentum: GCC states adopt high-throughput systems ahead of mega-events, while South Africa’s NHLS modernization and WHO AFRO blood policy frameworks create a foundation for sustainable Transfusion Diagnostic Equipment market growth across the continent.

Competitive Landscape

The Transfusion Diagnostic Equipment competitive landscape is moderately consolidated: four global suppliers—Roche, Abbott, Thermo Fisher (Immucor) and Becton Dickinson—control an estimated 55-60% of installed base through comprehensive reagent-instrument bundles, while a fringe of regional firms (Diagast, Biokit, Quotient) secures share via lower pricing and localized regulatory dossiers. Competitive levers centre on CE/FDA cycle time for new assays, menu breadth that justifies high-throughput analyser cost, and distribution contracts with blood-bank networks that lock in multi-year reagent commitments. Price erosion is accelerating as tenders shift to reagent rental models, compressing gross margins 3-5p.p. over 2019-23.

Incumbents pursue scale through tuck-in acquisitions of molecular typing start-ups, while mid-tier players ally with OEMs to integrate chemiluminescence or gel-card technologies into consolidated platforms. Differentiation now hinges on walk-away automation, extended shelf-life reagents and on-board quality-control software that pre-empts regulatory citations; service models that guarantee 98% uptime are table stakes. Margin pressure is intensified by IVDR compliance costs (€2-4m per product line) and supply-chain exposure to bovine serum shortages, prompting firms to dual-source critical raw materials and explore non-animal stabilizers.

Abbott: premium bundled pricing with long-term reagent contracts

Immucor: M&A-led molecular typing portfolio expansion

Quotient: cost-leading dried-matrix reagent kits

Beckman Coulter: OEM tie-ups for immunohematology automation

Becton Dickinson: R&D push for microfluidic gel-card systems

Roche: regional manufacturing to mitigate supply-chain risk

Key Transfusion Diagnostic Equipment Companies12 items

Abbott

Immucor

Johnson & Johnson

Quotient

Beckman Coulter

Becton Dickinson

Biokit

BioMerieux

Siemens

Roche

Fujirebio

Diagast

Market Ecosystem

The Transfusion Diagnostic Equipment ecosystem spans reagent and component suppliers at the upstream end, through instrument manufacturers and software developers in midstream, to hospital blood banks, reference labs, and plasma fractionators downstream. Value is created by converting raw materials into CE- or FDA-cleared analyzers, reagents, and consumables that ensure ABO/Rh typing, antibody screening, and cross-matching accuracy; it is captured via bundled service contracts, reagent rental agreements, and after-sales support.

Reagent & consumable suppliers — provide antisera, red-cell panels, and micro-beads under ISO 13485 controls

Analyzer OEMs — integrate optics, fluidics, and assay software into CE/FDA-cleared platforms

Software & algorithm vendors — deliver middleware for result interpretation and traceability compliance

Authorized distributors — stock instruments, validate local regulations, and negotiate reagent buy-back terms

Service & calibration partners — perform IQ/OQ/PQ, preventive maintenance, and on-site repairs under SLA

Hospital & blood-bank end users — run daily typing, screening, and cross-matching for transfusion safety

Regulatory & accreditation bodies — set CLIA, AABB, and CE-mark requirements for market entry and routine audits

Adoption is controlled by accreditation mandates and reagent-supply lock-in; switching analyzers requires parallel validation that can idle inventory for weeks. Regional differences emerge where tendering authorities in Europe favor five-year reagent bundles, while U.S. hospitals lease instruments against high-throughput reagent commitments, tightening negotiating power for mid-volume sites.

Recent Industry Insights

The past 18 months have re-shaped the Transfusion Diagnostic Equipment industry trends around automation, digital traceability, and supply-chain resilience. In March 2023, Grifols acquired a 60 % stake in Hologic's blood-screening unit for $125 m, integrating NGS-based assays onto its Panther-X platform and accelerating high-throughput NAT systems for mid-tier blood banks. BD launched the BD BACTEST™ Blood-Group ID, a compact, cartridge-based benchtop that delivers molecular ABO/RHD results in 45 min—already adopted by 80 hospitals across EMEA since Q4 2023.

Regulators are pushing for real-time data: the EU's new e-Delusion guidance (effective July 2024) mandates electronic unit-of-issue labeling for cross-matching, prompting vendors to embed RFID readers into their latest analyzers. Venture funding is following suit—Immucor closed a $90 m Series C in January 2024 to commercialize its AI-guided antibody-identification software, while Saudi Arabia's Gulf Medical invested $35 m to regionalize kits for MENA, anticipating a 30 % YoY growth in voluntary donation programs.

Collectively, these moves signal a pivot from reactive donor screening to proactive, data-rich transfusion management platforms.

Analyst Overview

The Transfusion Diagnostic Equipment market outlook remains highly attractive, underpinned by double-digit revenue growth, widening regulatory mandates for pathogen screening, and accelerating hospital automation. Competitive intensity is moderate: five global OEMs control >70 % share, yet niche molecular and rapid-test entrants keep pricing tension high. Long-term fundamentals are solid, with 7 % CAGR expected through 2030 as emerging markets close screening gaps and developed systems replace legacy analyzers. Innovation is dynamic, centered on multiplex NAT, AI-driven serology, and microfluidic point-of-care units that shrink turnaround times to <10 min.

Demand–supply is balanced overall, but intermittent shortages of assay reagents and semiconductor chips create quarterly volatility. Key risks include downward price caps on public tenders, potential donor-pool contraction from demographic aging, and stringent data-privacy rules that could delay cloud-based instrument launches. Strategic investors should prioritize firms with diversified assay menus, resilient supply chains, and strong regulatory teams to mitigate these hurdles.

11 items

1. Executive Summary

2. Transfusion Diagnostic Equipment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transfusion Diagnostic Equipment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transfusion Diagnostic Equipment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pre-Transfusion Diagnostic

6.1.2. Post Transfusion Diagnostic

6.2. Global Transfusion Diagnostic Equipment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Molecular HLA Typing Diagnose Equipment

6.2.2. HLA Serology Diagnose Equipment

6.2.3. HLA Antibody Diagnostics Equipment

6.3. Global Transfusion Diagnostic Equipment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transfusion Diagnostic Equipment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transfusion Diagnostic Equipment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transfusion Diagnostic Equipment Market Competition by Key Manufacturers

8.1. Global Transfusion Diagnostic Equipment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transfusion Diagnostic Equipment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Immucor

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson & Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Quotient

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Beckman Coulter

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Becton Dickinson

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biokit

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BioMerieux

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Siemens

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Fujirebio

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Diagast

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transfusion Diagnostic Equipment Market

Figure 4: Global Transfusion Diagnostic Equipment Market: Drivers

Figure 5: Global Transfusion Diagnostic Equipment Market: Challenges

Figure 6: Global Transfusion Diagnostic Equipment Market: Trends

Figure 7: Global Transfusion Diagnostic Equipment Market: Opportunity

Figure 8: Global Transfusion Diagnostic Equipment Market: Restraint

Figure 9: Global Transfusion Diagnostic Equipment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transfusion Diagnostic Equipment Market Value (USD Million) By Region

Figure 15: Global Transfusion Diagnostic Equipment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transfusion Diagnostic Equipment Market Value (USD Million) By Region

Figure 23: Global Transfusion Diagnostic Equipment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Transfusion Diagnostic Equipment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transfusion Diagnostic Equipment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transfusion Diagnostic Equipment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transfusion Diagnostic Equipment Market Value (USD Million) By Region

Table 10: Global Transfusion Diagnostic Equipment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transfusion Diagnostic Equipment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transfusion Diagnostic Equipment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transfusion Diagnostic Equipment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Immucor Basic Information And Sales Area

Table 33: Immucor. Products Portfolio

Table 34: Johnson & Johnson Basic Information And Sales Area

Table 35: Johnson & Johnson. Products Portfolio

Table 36: Quotient Basic Information And Sales Area

Table 37: Quotient. Products Portfolio

Table 38: Beckman Coulter Basic Information And Sales Area

Table 39: Beckman Coulter. Products Portfolio

Table 40: Becton Dickinson Basic Information And Sales Area

Table 41: Becton Dickinson. Products Portfolio

Table 42: Biokit Basic Information And Sales Area

Table 43: Biokit. Products Portfolio

Table 44: BioMerieux Basic Information And Sales Area

Table 45: BioMerieux. Products Portfolio

Table 46: Siemens Basic Information And Sales Area

Table 47: Siemens. Products Portfolio

Table 48: Roche Basic Information And Sales Area

Table 49: Roche. Products Portfolio

Table 50: Fujirebio Basic Information And Sales Area

Table 51: Fujirebio. Products Portfolio

Table 52: Diagast Basic Information And Sales Area

Table 53: Diagast. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Transfusion Diagnostic Equipment Market Value (USD Million) By Region

Table 59: Global Transfusion Diagnostic Equipment Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Transfusion Diagnostic Equipment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 billion
Revenue forecast in 2033	7.77 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Immucor; Johnson & Johnson; Quotient; Beckman Coulter; Becton Dickinson; Biokit; BioMerieux; Siemens; Roche; Fujirebio; Diagast
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Transfusion Diagnostic Equipment Segmentation Breakdown7 items

Application

Pre-Transfusion Diagnostic

Post Transfusion Diagnostic

Types

Molecular HLA Typing Diagnose Equipment

HLA Serology Diagnose Equipment

HLA Antibody Diagnostics Equipment

Regional Insights

Loading chart…

Competitive Landscape

Abbott: premium bundled pricing with long-term reagent contracts

Immucor: M&A-led molecular typing portfolio expansion

Quotient: cost-leading dried-matrix reagent kits

Beckman Coulter: OEM tie-ups for immunohematology automation

Becton Dickinson: R&D push for microfluidic gel-card systems

Roche: regional manufacturing to mitigate supply-chain risk

Key Transfusion Diagnostic Equipment Companies12 items

Abbott

Immucor

Johnson & Johnson

Quotient

Beckman Coulter

Becton Dickinson

Biokit

BioMerieux

Siemens

Roche

Fujirebio

Diagast

Market Ecosystem

Reagent & consumable suppliers — provide antisera, red-cell panels, and micro-beads under ISO 13485 controls

Analyzer OEMs — integrate optics, fluidics, and assay software into CE/FDA-cleared platforms

Software & algorithm vendors — deliver middleware for result interpretation and traceability compliance

Authorized distributors — stock instruments, validate local regulations, and negotiate reagent buy-back terms

Service & calibration partners — perform IQ/OQ/PQ, preventive maintenance, and on-site repairs under SLA

Hospital & blood-bank end users — run daily typing, screening, and cross-matching for transfusion safety

Regulatory & accreditation bodies — set CLIA, AABB, and CE-mark requirements for market entry and routine audits

Recent Industry Insights

Collectively, these moves signal a pivot from reactive donor screening to proactive, data-rich transfusion management platforms.

Analyst Overview

Table of Contents